New Data From Oxford University Hospitals Demonstrate Superior Outcome With CERAMENT™ Antibiotic Eluting Bone Substitute Compared To Collagen And Calcium Sulfate In The Management Of Chronic Osteomyelitis

- 50% Less Fracture Rates with CERAMENT™ with Gentamicin

- 50% Less Infection Recurrence with CERAMENT™ with Gentamicin

- 313 Patients Total in All Groups with a Minimum of 1 Year Follow-Up

LUND, Sweden, Oct. 6, 2015 /PRNewswire/ -- BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced new data from the Bone Infection Unit at the Nuffield Orthopaedic Centre (part of Oxford University Hospitals) as presented at the recent European Bone & Joint Infection Society (EBJIS) meeting.  The study, a comparative evaluation of three local antibiotic delivery materials used as bone defect fillers after excision of chronic osteomyelitis, found CERAMENT™ with Gentamicin performed better in all primary outcomes; recurrence rate, fracture rate and wound leakage rate, despite a higher percentage of compromised Class B hosts.  The three study groups encompassed a total of 313 patients each with a minimum 1- year follow-up.  The group including CERAMENT™ with Gentamicin resulted in fifty percent less fractures, fifty percent less infection recurrences and fewer prolonged wound leaks as compared with the collagen or calcium sulfate products. 

"These study results further support the potential benefit of CERAMENT™|G in the management of chronic osteomyelitis," said Martin McNally, Lead Surgeon of the Bone Infection Unit at the Nuffield Orthopaedic Centre in Oxford, UK and President-Elect of EBJIS.  "We believe the high level of antibiotics combined with a highly controlled release profile as well as the consistent bone remodeling contributed to the superior performance of CERAMENT™|G."

CERAMENT™|G is the first antibiotic eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis.

"We are extremely pleased with the performance of CERAMENT™|G in this study," said Lloyd Diamond, CEO of BONESUPPORT™.  "Not only did CERAMENT™|G outperform in all outcome measures, it did so with a higher percentage of highly compromised patients which is most impressive."

About BONESUPPORT™

BONESUPPORT™ is an emerging leader of injectable bone graft substitutes for orthopedics, and trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT™|G and CERAMENT™|V are the first CE-marked injectable antibiotic eluting ceramic bone graft substitutes indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections). CERAMENT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT™|G and CERAMENT™|V are not available in the United States.

CERAMENT™ is a fully developed product platform that is commercially available in the U.S., Europe, SE Asia and the Middle East. CERAMENT™ is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT™ spans more than eleven years. Over fifty pre-clinical, clinical and animal studies have been conducted and more than 20,000 patients have been treated with CERAMENT™.  The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT™ please visit www.bonesupport.com.

Press Inquiries:
Offer Nonhoff
Chief Financial Officer
[email protected]
Phone [phone]

PR 0450-01 en

SOURCE BONESUPPORT